

---

**THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION**

---

**If you are in any doubt** as to any aspect of this circular or as to the action you should take, you should consult your stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser.

**If you have sold or transferred** all your securities in **CHINA MEDICAL & HEALTHCARE GROUP LIMITED**, you should at once hand this circular with the accompanying form of proxy and the 2016/2017 Annual Report to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

---



## **China Medical & HealthCare Group Limited**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 383)**

### **GENERAL MANDATES TO REPURCHASE AND ISSUE SECURITIES RE-ELECTION OF DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING**

---

A notice convening an annual general meeting of China Medical & HealthCare Group Limited (the “**Company**”) to be held at Plaza 1 & 2, Lower Lobby, Novotel Century Hong Kong, 238 Jaffe Road, Wanchai, Hong Kong on Thursday, 7 December 2017 at 11:00 a.m. is set out in Appendix III on pages 13 to 16 of this circular. A form of proxy for use at the annual general meeting is also enclosed.

Whether or not you are able to attend the annual general meeting, you are requested to complete the enclosed form of proxy and return it in accordance with the instructions printed thereon and return the same to the office of the branch share registrars of the Company in Hong Kong, Tricor Tengis Limited at Level 22, Hopewell Centre, 183 Queen’s Road East, Hong Kong as soon as possible and in any event not later than 48 hours before the time appointed for holding of the annual general meeting or any adjournment thereof.

Completion and return of the form of proxy will not preclude you from attending and voting at the annual general meeting or any adjournment thereof if you so wish.

31 October 2017

---

## LETTER FROM THE BOARD

---



### China Medical & HealthCare Group Limited

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 383)**

*Executive Directors:*

Ms. Chong Sok Un (*Deputy Chairman*)  
Dr. Jonathan Weiyan Seah (*Chief Executive Officer*)  
Dato' Wong Peng Chong  
Mr. Kong Muk Yin

*Registered Office:*

Canon's Court  
22 Victoria Street  
Hamilton HM 12  
Bermuda

*Non-Executive Directors:*

Dr. Lim Cheok Peng (*Chairman*)  
Mr. Liao Feng

*Head Office and Principal Place of  
Business in Hong Kong:*

47th Floor  
China Online Centre  
333 Lockhart Road  
Wan Chai  
Hong Kong

*Independent Non-Executive Directors:*

Mr. Lau Siu Ki  
Mr. Zhang Jian  
Dr. Xia Xiaoning

31 October 2017

*To the shareholders of the Company*

Dear Sir or Madam,

**GENERAL MANDATES TO REPURCHASE AND ISSUE SECURITIES  
RE-ELECTION OF DIRECTORS  
AND  
NOTICE OF ANNUAL GENERAL MEETING**

**1. INTRODUCTION**

The purpose of this circular is to provide shareholders of the Company (the “**Shareholder(s)**”) with information regarding the resolutions to be proposed at an annual general meeting of the Company to be held on 7 December 2017 (the “**Annual General Meeting**”).

---

## LETTER FROM THE BOARD

---

### 2. GENERAL MANDATES TO REPURCHASE AND ISSUE BY THE COMPANY OF ITS SECURITIES

At the annual general meeting of the Company held on 8 December 2016, a general mandate was given to the directors of the Company (the “**Director(s)**”) to exercise the powers of the Company to repurchase its securities. Such mandate will lapse at the conclusion of the Annual General Meeting.

An ordinary resolution will be proposed to give a fresh general mandate to the Directors to exercise the powers of the Company to repurchase, for a term and in the terms as stated in the said ordinary resolution, shares of HK\$0.0005 each of the Company (the “**Shares**”) in and up to a maximum of 10% of the aggregate nominal amount of the issued share capital of the Company at the date of passing such ordinary resolution (the “**Repurchase Mandate**”).

An explanatory statement, as required under the relevant rules set out in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”) regarding the repurchase by companies with primary listings on the Stock Exchange of their own securities to provide the requisite information on the Repurchase Mandate, is set out in Appendix I hereto.

In addition to the ordinary resolution regarding the Repurchase Mandate, two other ordinary resolutions will also be proposed at the Annual General Meeting, one of which purports to grant to the Directors a general mandate to allot, issue and deal with additional Shares not exceeding 20% of the aggregate nominal amount of the issued share capital of the Company at the date of passing of such resolution (the “**Issue Mandate**”); and another which purports to extend the limit under such Issue Mandate if granted to the Directors the number of Shares representing the aggregate nominal amount of the Shares in the issued capital of the Company repurchased by the Company under the Repurchase Mandate (the “**Extension Mandate**”).

Assuming that there is no change in the issued share capital of the Company from the Latest Practicable Date to the date of passing the relevant resolution, the maximum number of Shares that may be issued pursuant to the Issue Mandate is 2,896,014,554.

### 3. RE-ELECTION OF DIRECTORS

Pursuant to Clause 99 of the Bye-Laws of the Company (the “**Bye-Laws**”), Dato’ Wong Peng Chong, Mr. Kong Muk Yin and Mr. Zhang Jian shall retire from the office by rotation at the forthcoming Annual General Meeting. Dato’ Wong Peng Chong, Mr. Kong Muk Yin and Mr. Zhang Jian, being eligible, will offer themselves for re-election at the Annual General Meeting.

---

## LETTER FROM THE BOARD

---

Mr. Zhang Jian has served on the board of Directors of the Company (the “**Board**”) as an independent non-executive Director for more than nine years and, during such tenure, he has given independent guidance and advice to the Company. The Company has received from Mr. Zhang Jian his annual confirmation of independence pursuant to Rule 3.13 of the Listing Rules. The Board is satisfied that Mr. Zhang Jian remains independent, and considers that Mr. Zhang Jian would be able to continue to discharge his duties as an independent non-executive director of the Company and should be re-elected at the Annual General Meeting subject to a separate resolution to be approved by the Shareholders pursuant to the requirement of the Listing Rules, particularly in view of his extensive experience and valuable contribution to the Board.

Pursuant to Clause 102 of the Bye-Laws, Dr. Xia Xiaoning will retire and being eligible, offer himself for re-election at the forthcoming Annual General Meeting.

At the Annual General Meeting, ordinary resolutions to re-elect retiring Directors, Dato’ Wong Peng Chong, Mr. Kong Muk Yin, Dr. Xia Xiaoning and Mr. Zhang Jian will be proposed in accordance with the Bye-Laws.

Details of the Directors being subject to retirement by rotation and re-election, as required to be disclosed under Chapter 13 of the Listing Rules, are set out in Appendix II hereto.

#### **4. ANNUAL GENERAL MEETING**

The contents of the ordinary resolutions to be proposed at the Annual General Meeting are set out in Appendix III hereto.

A form of proxy for use at the Annual General Meeting is enclosed hereto. Whether or not you intend to attend the Annual General Meeting, you are requested to complete the enclosed form of proxy and return it in accordance with the instructions printed thereon and return the same to the office of the branch share registrars of the Company in Hong Kong, Tricor Tengis Limited at Level 22, Hopewell Centre, 183 Queen’s Road East, Hong Kong as soon as possible and in any event not later than 48 hours before the time appointed for holding of the Annual General Meeting or any adjournment thereof. Completion and return of the form of proxy will not preclude you from attending and voting in person at the Annual General Meeting or any adjournment thereof if you so wish.

Pursuant to Rule 13.39(4) of the Listing Rules, any vote of Shareholders at a general meeting must be taken by poll. Accordingly, all resolutions will be put to vote by way of poll at the Annual General Meeting. Any announcement on the results of the vote by poll will be made by the Company after the Annual General Meeting in the manner prescribed under Rule 13.39(5) of the Listing Rules.

---

## LETTER FROM THE BOARD

---

### 5. RECOMMENDATION

The Directors believe that the proposed ordinary resolutions for the Repurchase Mandate, Issue Mandate, Extension Mandate and re-election of Directors are all in the best interests of the Company and its Shareholders as a whole. Accordingly, the Directors recommend that you vote in favour of all the aforesaid proposed resolutions at the Annual General Meeting.

This notice of Annual General Meeting dated 31 October 2017 is set out in Appendix III of this circular.

Should there be any inconsistencies between the English text and the Chinese text of this circular, the English text of this circular will prevail over the Chinese text.

By Order of the Board  
**China Medical & HealthCare Group Limited**  
**Dr. Lim Cheok Peng**  
*Chairman*

*This appendix serves as an explanatory statement, as required by the Listing Rules, to provide the requisite information to you for your consideration of the Repurchase Mandate.*

## **1. SHARE CAPITAL**

As at 26 October 2017 (the latest practicable date prior to the printing of this circular, the “**Latest Practicable Date**”), there were in issue an aggregate of 14,480,072,773 Shares.

Subject to the passing and pursuant to the terms of the ordinary resolution regarding the Repurchase Mandate and on the basis that no further Shares are issued or repurchased prior to the Annual General Meeting to be held on 7 December 2017, the Company would be allowed under the Repurchase Mandate to repurchase a maximum of 1,448,007,277 Shares.

## **2. REASONS FOR REPURCHASE**

The Directors believe that the Repurchase Mandate is in the best interests of the Company and its Shareholders as a whole. Such repurchase may, depending on market conditions and funding arrangements at the time, lead to an enhancement of the net assets value per share and/or earnings per share and will only be made when the Directors believe that such repurchase will benefit the Company and its Shareholders as a whole.

## **3. FUNDING OF REPURCHASE AND MATERIAL ADVERSE IMPACT**

In repurchasing Securities, the Company may only apply funds legally available for such purpose in accordance with its Memorandum of Association and Bye-Laws and the laws of Bermuda. The amount of premium payable on repurchase may only be paid out of either the profits that would otherwise be available for dividend or out of the share premium or contributed surplus accounts of the Company.

There might be an adverse impact on the working capital or gearing position of the Company as compared with the position disclosed in the audited consolidated financial statements contained in its annual report for the year ended 30 June 2017 in the event that the Repurchase Mandate were to be exercised in full at any time during the proposed repurchase period. However, the Directors do not propose to exercise the Repurchase Mandate to such extent as would, in the circumstances, have a material adverse effect on the working capital requirements or the gearing levels of the Company which in the opinion of the Directors are from time to time appropriate for the Company.

#### 4. SHARE PRICES

The highest and lowest prices at which the Shares of the Company have traded on the Stock Exchange during the current month and each of the previous twelve months before the printing of this circular were as follows:–

	Shares	
	Highest <i>HK\$</i>	Lowest <i>HK\$</i>
<b>2016</b>		
October	0.450	0.360
November	0.440	0.405
December	0.475	0.380
<b>2017</b>		
January	0.415	0.380
February	0.415	0.385
March	0.410	0.370
April	0.435	0.360
May	0.390	0.355
June	0.365	0.310
July	0.370	0.295
August	0.380	0.315
September	0.340	0.290
October (up to the Latest Practicable Date)	0.320	0.275

#### 5. UNDERTAKING AND EFFECT OF REPURCHASE

The Directors have undertaken to the Stock Exchange that, so far as the same may be applicable, they will exercise the powers of the Company to make repurchases pursuant to the Repurchase Mandate and in accordance with the Listing Rules and the laws of Bermuda.

None of the Directors nor, to the best of their knowledge having made all reasonable enquiries, their associates as defined in the Listing Rules, have any present intention to sell any securities of the Company to the Company or its subsidiaries under the Repurchase Mandate if such is approved by the Shareholders.

No connected person (as defined in the Listing Rules) has notified the Company that it has a present intention to sell securities of the Company to the Company or its subsidiaries or have undertaken not to do so, in the event that the Repurchase Mandate is approved by the Shareholders.

If a Shareholder's proportionate interest in the voting rights of the Company increases upon exercise of the powers to repurchase securities of the Company pursuant to the Repurchase Mandate, such increase will be treated as an acquisition for the purposes of the Hong Kong Code on Takeovers and Mergers (the "**Takeovers Code**"). As a result, a Shareholder or group of Shareholders acting in concert, depending on the level of increase of the Shareholder's interest, could obtain or consolidate control of the Company and become obliged to make a mandatory general offer for all Shares in issue at the time in accordance with Rule 26 of the Takeovers Code.

As at the Latest Practicable Date, 同方股份有限公司 (Tsinghua Tongfang Co., Ltd.) ("**THTF**") beneficially held 4,000,000,000 ordinary shares of the Company (*Note*) (approximately 27.62% of the issued share capital of the Company).

In the event that the Directors exercise in full the power to repurchase Shares which is proposed to be granted pursuant to the Repurchase Mandate then (if the present Shareholders' interests in Shares remained the same) the attributable shareholding of THTF in the Company would be increased to approximately 30.69% of the issued share capital of the Company. Such increase may give rise to an obligation to make a mandatory offer under Rule 26 of the Takeover Code. However, the Directors have no current intention to exercise the Repurchase Mandate to such an extent as would give rise to this obligation. In any event, the Repurchase Mandate will be exercised only if the number of Shares held by the public would not fall below 25%.

*Note:*

Cool Clouds Limited, a wholly-owned subsidiary of Resuccess Investments Limited ("**Resuccess Investments**"), owns 4,000,000,000 ordinary shares of the Company. THTF maintains 100% beneficial interests in Resuccess Investments. Accordingly, Resuccess Investments and THTF are deemed to have interests in 4,000,000,000 ordinary shares of the Company.

## 6. SECURITIES REPURCHASE MADE BY THE COMPANY

In the six months immediately preceding the Latest Practicable Date, the Company has not repurchased any of its shares on the Stock Exchange or otherwise.



*The followings are the details of the retiring Directors of the Company proposed to be re-elected at the Annual General Meeting:–*

**(i) Dato' Wong Peng Chong (“Dato' Wong”)**

**Dato' Wong Peng Chong**, aged 73, was appointed as executive director of the Company on 15 March 2002. Dato' Wong is a non-executive director of Manfield Chemical Holdings Limited. He is also a director of Asia Development Capital Co., Ltd., a company listed on The Tokyo Stock Exchange, Inc..

Upon his graduation from the University of Malaya in 1967, Dato' Wong joined the Malaysian Foreign Service and served with several Malaysian diplomatic missions overseas in various capacities. He joined the private sector in 1985 and has served in various senior management positions, including executive directorships in public listed companies, in Hong Kong and Malaysia. He was the vice-president of Alibaba Pictures Group Limited from 4 July 2007 to 9 December 2009 and executive director of Landing International Development Limited from 13 October 2009 to 21 January 2010. He was also a director of Mabuhay Holdings Corporation from 23 June 2009 to 27 July 2017 and IRC Properties, Inc. from 6 November 2009 to 27 July 2017 respectively, companies listed on The Philippine Stock Exchange, Inc..

Pursuant to the service agreement entered into between Dato' Wong and the Company, the term of his service if re-elected at the Annual General Meeting, he shall continue for a period of two years and shall be renewed automatically for successive 2-year term or until terminated in accordance with the said service agreement. His appointment is also subject to the relevant provisions of retirement and re-election at the annual general meetings of the Company in accordance with the Bye-Laws or any other applicable laws whereby he shall vacate his office. Dato' Wong is entitled to receive a monthly remuneration of HK\$120,000, one month year-end double pay and a performance based discretionary bonus. His remuneration is determined by reference to the market salary range for the position.

As at the Latest Practicable Date, Dato' Wong has no interest in the Shares within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (“SFO”).

**(ii) Mr. Kong Muk Yin (“Mr. Kong”)**

**Mr. Kong Muk Yin**, aged 51, was appointed as executive director of the Company on 13 May 2002. He is a non-executive director and company secretary of Manfield Chemical Holdings Limited. From 4 July 2007 to 24 June 2014, he was also an executive director and non-executive director of Alibaba Pictures Group Limited. He was an executive director of Landing International Development Limited from 13 October 2009 to 21 January 2010 and an executive director of APAC Resources Limited from 4 November 2009 to 1 March 2016. During September 2010 to September 2015, he was also a director of Mabuhay Holdings Corporation and IRC Properties, Inc., companies listed on The Philippine Stock Exchange, Inc..

Mr. Kong was graduated from City University of Hong Kong with a bachelor’s degree in business studies. He is a fellow member of The Association of Chartered Certified Accountants, a member of the Hong Kong Institute of Certified Public Accountants and a Chartered Financial Analyst and he has extensive experience in corporate finance, financial management, accounting and auditing.

Pursuant to the service agreement entered into between Mr. Kong and the Company, the term of his service if re-elected at the Annual General Meeting, he shall continue for a period of two years and shall be renewed automatically for successive 2-year term or until terminated in accordance with the said service agreement. His appointment is also subject to the relevant provisions of retirement and re-election at the annual general meetings of the Company in accordance with the Bye-Laws or any other applicable laws whereby he shall vacate his office. Mr. Kong is entitled to receive a monthly remuneration of HK\$120,000, one month year-end double pay and a performance based discretionary bonus. His remuneration is determined by reference to the market salary range for the position.

As at the Latest Practicable Date, Mr. Kong has no interest in the Shares within the meaning of Part XV of the SFO.

**(iii) Dr. Xia Xiaoning (“Dr. Xia”)**

**Dr. Xia Xiaoning**, aged 57, was appointed as independent non-executive director of the Company on 8 December 2016. Dr. Xia is an independent supervisor of Central China Securities Co., Ltd. (a company listed on the Main Board of The Stock Exchange of Hong Kong Limited, Stock Code: 1375). He was a non-executive director of Mason Group Holdings Limited (formerly known as Mason Financial Holdings Limited) (a company listed on the Main Board of The Stock Exchange of Hong Kong Limited, Stock Code: 273) from August 2015 to September 2016. Dr. Xia graduated from the Electric Engineering Department of Harbin Institute of Technology in 1982 with a bachelor degree in electric engineering. He earned a doctorate degree from University Paris Dauphine in 1989. Dr. Xia is a Chartered Financial Analyst.

Dr. Xia has over 23 years private equity/investment experience in Asia. Dr. Xia was a senior consultant/Responsible Officer (SFC Type 4 and Type 9) to Vision Finance Group Limited from October 2012 to February 2015. From 2008 to 2012, he was the Chief Executive Officer of CITP Advisors (Hong Kong) Limited. Dr. Xia worked for AIF Capital Limited (“AIF”), a pan Asia private equity firm based in Hong Kong from 1995 to 2008 and his last position with AIF was Senior Partner/Managing Director. Dr. Xia also worked for Asian Development Bank in Manila from 1989 to 1995 with his last position as investment officer.

Pursuant to the letter of appointment entered into between Dr. Xia and the Company, the term of his service, if re-elected at the Annual General Meeting, he shall continue for a period of two years and shall be renewed automatically for successive 2-year term or until terminated in accordance with the said letter of appointment. His appointment is also subject to the relevant provisions of retirement and re-election at the annual general meetings of the Company in accordance with the Bye-Laws or any other applicable laws whereby he shall vacate his office. Dr. Xia will be entitled to receive HK\$220,000 per annum as director’s remuneration which is determined by reference to the market salary range for the position.

As at the Latest Practicable Date, Dr. Xia has no interest in the Shares within the meaning of Part XV of the SFO.

Save as disclosed above, Dr. Xia did not hold any directorship in other listed public companies in Hong Kong or overseas in the last three years and does not have any relationship with any other Directors, senior management, substantial or controlling shareholders of the Company.

**(iv) Mr. Zhang Jian (“Mr. Zhang”)**

**Mr. Zhang Jian**, aged 75, was appointed as independent non-executive director of the Company on 16 October 2006. Mr. Zhang is an independent non-executive director of Go Higher Environment Co., Ltd.. He is also a professional senior engineer in PRC and the Chairman of Xian University of Architecture & Technology Peking Alumni Association. He has been awarded National Outstanding Intellect in 1997 and National Top 10 Honest Persons of Outstanding Ability in 2004. Mr. Zhang has been awarded as Influential Person to China Nonferrous Metal Industry in 2005. From 1982 to 1998, he held various senior positions in China Nonferrous Metal Industry Company. From 1998 to 2003, he acted as Chairman and General Manager of China Nonferrous Metal Construction Group Company Ltd.. From 2003 to 2005, he acted as General Manager of China Nonferrous Metal Mining & Construction (Group) Co., Ltd..

Pursuant to the letter of appointment entered into between Mr. Zhang and the Company, the term of his service, if re-elected at the Annual General Meeting, he shall continue for a period of two years and shall be renewed automatically for successive 2-year term or until terminated in accordance with the said letter of appointment. His appointment is also subject to the relevant provisions of retirement and re-election at the annual general meetings of the Company in accordance with the Bye-Laws or any other applicable laws whereby he shall vacate his office. Mr. Zhang is entitled to receive HK\$100,000 per annum as Director’s remuneration which is determined by reference to the market salary range for the position.

As at the Latest Practicable Date, Mr. Zhang has no interest in the Shares within the meaning of Part XV of the SFO.

Mr. Zhang has served on the Board as an independent non-executive Director for more than nine years since 16 October 2006 and, during such tenure, he has given independent guidance and advice to the Company. The Company has received annual confirmation of independence from Mr. Zhang pursuant to Rule 3.13 of the Listing Rules.

The Board is satisfied that Mr. Zhang remains independent, and considers that Mr. Zhang would be able to continue to discharge his duties as an independent non-executive director of the Company and should be re-elected at the Annual General Meeting, particularly in view of his extensive experience and valuable contribution to the Board.

Save as disclosed above, Mr. Zhang did not hold any directorship in other listed public companies in Hong Kong or overseas in the last three years and does not have any relationship with any other Directors, senior management, substantial or controlling shareholders of the Company.

Save as disclosed above, there are no other matters concerning Dato’ Wong Peng Chong, Mr. Kong Muk Yin, Dr. Xia Xiaoning and Mr. Zhang Jian relating to their re-election that need to be brought to the attention of the Shareholders and there is no other information that is required to be disclosed pursuant to Rules 13.74 and 13.51(2)(a) to 13.51(2)(v) of the Listing Rules.



## China Medical & HealthCare Group Limited

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 383)**

### NOTICE OF ANNUAL GENERAL MEETING

**NOTICE IS HEREBY GIVEN** that the Annual General Meeting (“**Meeting**”) of the Company will be held at Plaza 1 & 2, Lower Lobby, Novotel Century Hong Kong, 238 Jaffe Road, Wanchai, Hong Kong on Thursday, 7 December 2017 at 11:00 a.m. for the following purposes:–

#### ORDINARY RESOLUTIONS

As ordinary business, to consider and, if thought fit, pass with or without amendments the following resolutions as ordinary resolutions of the Company:–

1. To receive and consider the Audited Financial Statements and the Reports of the Directors and the Auditor for the year ended 30 June 2017.
2. To re-elect Directors (Dato’ Wong Peng Chong, Mr. Kong Muk Yin and Dr. Xia Xiaoning) and authorise the Board of Directors (the “**Board**”) to fix their remuneration.
3. To re-elect Director (Mr. Zhang Jian) and authorise the Board to fix his remuneration.
4. To re-appoint Auditor and authorise the Board to fix their remuneration.

As special business, to consider and, if thought fit, pass with or without amendments the following resolutions as ordinary resolutions of the Company:–

5. (i) “**THAT**:–
  - (a) subject to paragraph (b) below, the exercise by the directors of the Company (“**Directors**”) during the Relevant Period (as hereinafter defined) of all the powers of the Company to repurchase shares in the share capital of the Company or any other rights or securities to subscribe or purchase shares in the share capital of the Company in each case through the facilities of The Stock Exchange of Hong Kong Limited (“**Stock Exchange**”) or of another exchange recognised by the Securities and Futures Commission of Hong Kong and the Stock Exchange under the Hong Kong Code on Share Repurchases for this purpose, subject to and in accordance with all applicable laws and the requirements of the Rules Governing the Listing of Securities on the Stock Exchange or of any other stock exchange as amended from time to time, be and is hereby generally and unconditionally approved;

- (b) the aggregate nominal amount of share capital of the Company to be repurchased by the Company pursuant to the approval in paragraph (a) above shall not exceed ten per cent. (10%) of the aggregate nominal amount of share capital of the Company in issue at the date of passing this Resolution and the approval in paragraph (a) above shall be limited accordingly; and
- (c) for the purpose of this Resolution, “Relevant Period” means the period from the passing of this Resolution until whichever is the earlier of:–
  - (i) the conclusion of the next annual general meeting of the Company;
  - (ii) the expiration of the period within which the next annual general meeting of the Company is required by the laws of Bermuda or the Bye-Laws of the Company (the “**Bye-Laws**”) to be held; and
  - (iii) the date on which the authority set out in this Resolution is revoked or varied by an ordinary resolution of the shareholders in general meeting.”
- (ii) **“THAT:–**
  - (a) subject to paragraph (c) below, the exercise by the Directors during the Relevant Period (as hereinafter defined) of all the powers of the Company to allot, issue and deal with additional shares in the share capital of the Company or securities convertible into such shares or options, warrants or other rights to subscribe for any such shares or such convertible securities and to make or grant offers, agreements and options which would or might require the exercise of such power, be and is hereby generally and unconditionally approved;
  - (b) the approval in paragraph (a) above shall authorise the Directors during the Relevant Period (as hereinafter defined) to make or grant offers, agreements and options which would or might require the exercise of such power after the end of the Relevant Period;

- (c) the aggregate nominal amount of share capital of the Company to be allotted or agreed conditionally or unconditionally to be allotted (whether pursuant to an option or otherwise) and issued by the Directors pursuant to the approval in paragraph (a) above, otherwise than pursuant to (i) a Rights Issue (as hereinafter defined); (ii) an issue of shares as scrip dividends pursuant to the Bye-Laws from time to time; (iii) an issue of shares under any option scheme or similar arrangement for the time being adopted for the grant or issue to employees of the Company and/or any of its subsidiaries of shares or rights to acquire shares of the Company; or (iv) an issue of shares upon the exercise of rights of subscription or conversion under the terms of any warrants of the Company, shall not exceed twenty per cent. (20%) of the aggregate nominal amount of the issued share capital of the Company at the date of passing this Resolution, and the said approval in paragraph (a) above shall be limited accordingly; and
- (d) for the purpose of this Resolution, “Relevant Period” means the period from the passing of this Resolution until whichever is the earlier of:–
- (i) the conclusion of the next annual general meeting of the Company;
  - (ii) the expiration of the period within which the next annual general meeting of the Company is required by the laws of Bermuda or the Bye-Laws to be held; and
  - (iii) the date on which the authority set out in this Resolution is revoked or varied by an ordinary resolution of the shareholders in general meeting; and

“Rights Issue” means an offer of shares open for a period fixed by the Directors to the holders of shares of the Company on the register on a fixed record date in proportion to their holdings of such shares as at that date (subject to such exclusions or other arrangements as the Directors may deem necessary or expedient in relation to fractional entitlements or having regard to any restrictions or obligations under the laws of, or the requirements of any recognised regulatory body or any stock exchange in any territory outside Hong Kong applicable to the Company).”

- (iii) “**THAT** conditional upon the passing of Ordinary Resolutions Nos. 5 (i) and 5 (ii) above, the general mandate granted to the Directors to exercise the powers of the Company to allot, issue and deal with additional shares in the share capital of the Company pursuant to Ordinary Resolution No. 5 (ii) above be and is hereby extended by the addition thereto of an amount representing the aggregate nominal amount of issued share capital of the Company repurchased by the Company under the authority granted pursuant to the Ordinary Resolution No. 5 (i) above, provided that such amount shall not exceed ten per cent. (10%) of the aggregate nominal amount of the issued share capital of the Company at the date of passing this Resolution.”

By Order of the Board  
**China Medical & HealthCare Group Limited**  
**Fung Ching Man, Ada**  
*Company Secretary*

Hong Kong, 31 October 2017

*Notes:–*

- (i) Any member of the Company entitled to attend and vote at the Meeting or a meeting of the holder of any class of shares in the Company shall be entitled to appoint another person as his proxy to attend and vote instead of him. A proxy need not be a member of the Company. A member may appoint more than one proxy to attend on the same occasion.
- (ii) The instrument appointing a proxy shall be in writing under the hands of the appointor or of his attorney duly authorised in writing, or if the appointor is a corporation, either under seal, or under the hand of an officer or attorney duly authorised.
- (iii) The instrument appointing a proxy and the power of attorney or other authority, if any, under which it is signed or a notarially certified copy of that power or authority shall be deposited at the branch share registrars of the Company in Hong Kong, Tricor Tengis Limited at Level 22, Hopewell Centre, 183 Queen’s Road East, Hong Kong, not less than 48 hours before the time appointed for holding the Meeting or adjourned Meeting at which the person named in such instrument proposes to vote, and in default the instrument of proxy shall not be treated as valid.
- (iv) All voting by the members at the Meeting shall be conducted by way of poll.